Telix Pharmaceuticals Limited
TLX
$10.70
-$0.04-0.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.13M | 2.34M | 11.80M | 20.55M | 33.51M |
| Total Depreciation and Amortization | 20.95M | 16.69M | 12.43M | 9.23M | 5.27M |
| Total Amortization of Deferred Charges | 460.00K | 230.00K | -- | -- | -- |
| Total Other Non-Cash Items | 13.64M | 27.16M | 40.69M | 45.95M | 31.66M |
| Change in Net Operating Assets | -45.22M | -44.11M | -43.01M | -43.01M | -43.01M |
| Cash from Operations | -17.29M | 2.31M | 21.91M | 32.71M | 27.44M |
| Capital Expenditure | -25.69M | -19.21M | -12.72M | -10.86M | -9.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -229.03M | -233.16M | -237.30M | -138.03M | -23.20M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -31.20M | -48.15M | -65.10M | -61.27M | -54.31M |
| Cash from Investing | -285.92M | -300.52M | -315.11M | -210.17M | -86.60M |
| Total Debt Issued | 529.00K | 213.32M | 426.12M | 427.11M | 428.30M |
| Total Debt Repaid | -6.06M | -5.47M | -4.87M | -3.86M | -2.06M |
| Issuance of Common Stock | 1.81M | 1.36M | 918.00K | 891.20K | 716.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -4.86M | -9.71M | -7.83M | -10.65M |
| Cash from Financing | -3.72M | 204.36M | 412.45M | 416.31M | 416.81M |
| Foreign Exchange rate Adjustments | 8.80M | 8.85M | 8.90M | 782.80K | -1.93M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -298.13M | -84.99M | 128.15M | 239.64M | 355.71M |